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Summary
The earliest attempts at cell therapy can be attributed
to Charles-Edward Brown-Séquard (1817–1894), who
sought to treat senescence and aging by injecting animal
gonad shreds into his contemporaries, a practice that was
widespread in late 19th century. Since then, advances in
science have enabled the development of biological sub-
stitutes to restore the function of various tissues. Skin
was one of the first tissues to be regenerated. For severe
burns, patient survival depends on the restoration of skin
function as a barrier against pathogens and control of
body temperature and fluid loss. We aim here to overview
the different cell therapy techniques implemented at the
University Hospital of Lausanne (CHUV), one of the two
Swiss national centres of highly specialised medicine for
burn care. In particular, we will describe the specific indi-
cations for each of the different therapies as well as future
perspectives.
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Introduction
Throughout and across history, allusions to the artificial
generation of tissues and organs can be found in mytholo-
gy, literature or art, such as that illustrated in the “Healing
of Justinian” painting (278 AD), where the transplantation
of an artificial limb by Cosmas and Damien [1] is depicted.
About four decades ago, technological advances in bio-
medical sciences achieved the translation of this funda-
mental concept to practical approaches, thus giving birth
to the modern fields of tissue engineering and regenerative
medicine [2]. Langer and Vacanti, who are often referred
to as tissue engineering pioneers, defined tissue engineer-
ing as the interdisciplinary field that applies the principles
of engineering and life sciences to the development of bi-
ological substitutes that restore, maintain or improve the
function of tissues or whole organs [3]. Tissue engineering
has evolved from the field of biomaterials and now refers
to the combination of scaffolds, cells and biologically ac-
tive molecules into functional tissue constructs designed to
be implanted into damaged tissue [4]. Regenerative med-
icine has a broader research scope that not only includes
the concepts of tissue engineering, but also incorporates
the notion of self-healing, where the body uses its own sys-
tems with the help of foreign biomaterials to rebuild tis-
sues and organs. Tissue engineering and regenerative med-
icine have become largely interchangeable, as both fields
use cell therapy to cure complex wounds or diseases [5].
Because of their two-dimensional structure, skin and carti-
lage were considered good candidates to be the first tissues
to be engineered or regenerated using cell-based products
[6]. Although several examples of cell-based engineered
tissues have been approved in the USA by the Food and
Drug Administration (FDA), a lack of funding has limited
their evaluation in extensive clinical trials [7]. For burn
care, cell-based therapies have been implemented world-
wide for many years, and improved techniques have helped
to save many lives since they were first used in 1981 [8, 9].
There is a long history of using cell therapy in Switzerland.
Famous pioneering examples of Swiss-based therapy were
performed around 1930 by Paul Niehans, who harvested
embryonic cow cells to treat illustrious figures such as
Charlie Chaplin or Pope Pius XII [10]. With increased reg-
ulation for security, Swiss authorities (Federal Health Of-
fice and Swissmedic) have regulated such practices to en-
sure the overall safety of patients. With a high incidence
of cellular therapy use (>40 per 10 million population),
Switzerland had one of the highest rates of cell transplanta-
tion in Europe in 2009 [11]. Cell therapies are particularly
common for skin regeneration, especially at the University
Hospital of Lausanne (CHUV), which is one of only two
national centres specialised in burn care. Here, we aim to
give an overview of the history of the different cell ther-
apies used for skin regeneration in the burn unit at the
CHUV, and describe the techniques and the conditions un-
der which they are used, as well as highlight the regulatory
challenges and perspectives of cell therapies.
The degree of burn damage according to skin
structure
The skin is composed of three layers: the epidermis, dermis
and hypodermis (fig. 1). The outermost protective layer is
the epidermis, which is composed mainly of keratinocytes
and provides a barrier against pathogens [12]. The dermis,
the layer beneath the epidermis, contains the vasculature,
nerves and glands and is mainly composed of fibroblasts
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surrounded by an extracellular matrix of collagen and pro-
teoglycan, which provides the elasticity and tensile
strength of the skin [13]. Finally, the hypodermis or the
subcutaneous tissue is connective tissue that attaches the
skin to bone and muscles, and is mainly composed of adi-
pose tissue. Burn severity is classified according to the
depth of the wound and layers of skin that are effected: a
first degree burn involves only the epidermis, second de-
gree superficial is a wound of the upper half of the der-
mis, second degree deep involves almost all of the dermis,
and third degree burns reach the hypodermis. When a burn
wound is second degree deep / third degree, the vascula-
ture is destroyed and the body loses its capacity to self-re-
generate. Surgical procedures combined with cell therapies
thus become indispensable.
The cell type in a cell-based therapy
For a further understanding of the intricacies of cell ther-
apy approaches in skin regeneration for burns, we first in-
troduce the definitions of various cell types. Several cell
types from different stages of development that have dif-
ferent properties can be used in a cell-based therapy (fig.
2).
Stem cells can be of embryonic or adult origin. Embryonic
stem cells (ESCs) are derived from the inner cell mass of
a blastocyst and are pluripotent; they have the ability to
differentiate into all types of cells [14]. ESCs are multi-
potent at later stages of development (can develop into a
limited number of cell types in a particular lineage or tis-
sue [15]). Directing a uniform differentiation of ESCs into
the desired cell type with in vitro cell culture is challeng-
ing, as they require intense treatment with growth factors
to be fully and successfully differentiated; undifferentiated
ESCs carry a risk of creating tumours when transplanted
[16]. Adult stem cells can be multi- or unipotent cells that
reside in tissue-specific niches for tissue regeneration [17].
However, adult stem cells are difficult to identify as they
have a similar morphology to normal fibroblast-like cells
and require specific surface proteins to be distinguished
[18].
Progenitor cells, unlike stem cells, are cells of fetal origin
that are already specific to each organ, but are not fully dif-
ferentiated [19]. Progenitor cells have a higher regenera-
tive potential than other cells, minimise scarring and grow
rapidly in culture [20]. Also, progenitor cells maintain a
stable expression of markers specific to skin without addi-
tional growth factors during cell culture, unlike stem cells
[21].
Specialised cells are fully differentiated cells that are spe-
cific to each tissue. For skin, there are two main cell types,
keratinocytes and fibroblasts, as well as melanocytes,
Merkel cells and Langerhans cells [22].
In cell therapy, autologous transplants are where the cell
donor and recipient are the same person. For allogeneic
transplants, the cell donor and recipient are different indi-
viduals. One of the specialisations at the CHUV is the use
of both autologous and allogeneic progenitor cells for the
regeneration of skin in burn patients (fig. 3).
The use of progenitor cells has been part of the Federal
Organ Transplant Programme since 1991 and is registered
with the Swiss Federal Office of Public Health. Progenitor
Figure 1: The different degrees of burn wounds according to skin structure.
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cells do not induce a rejection reaction, unlike other
sources of allogeneic cells [23], which means that it could
be possible to create a universal cell bank allowing the
treatment of several patients from only one organ donation
[24]. Hundreds of biological bandages can be applied to
the patient within 24 hours, whereas an autologous cell
therapy requires a biopsy for each patient and culture for
several weeks (3–7, depending on technique).
Cell therapies utilised at the CHUV burn unit
Cell therapy has a long history at the burn unit of the
CHUV: the first cultured epithelial autograft (CEA) was
introduced into clinics as early as in 1985. For CEA, a
biopsy of the patient's epidermis (approximately 10 cm2)
is taken and digested to obtain keratinocytes. Cells expand
on a feeder layer and form stratified cell sheets in 14–21
days when cultured in the appropriate medium. This thin
layer of skin (keratinocyte sheet) can then be transferred
on Vaseline gauze and applied topically to the patient for
wound closure [25] (fig. 4a). In exceptional cases (1–2 cas-
es per year), where the patient’s condition does not allow
for a long delay in treatment, it is possible to apply ker-
atinocytes by spray instead of as a sheet in order to reduce
preparation time [26].
Cultured dermal-epidermal autograft (CDEA), which was
implemented in the mid-1990s, is based on the principle
of CEA, but allows re-creation of a thicker skin-graft, be-
cause a double layer composed of autologous fibroblasts
and keratinocytes is used [27]. CDEA provides a better
clinical outcome, with a skin graft having more functional
mechanical properties than a CEA. However, CDEA is less
commonly used since it requires a full thickness biopsy
and longer culture times, typically 6–7 weeks. CDEA is
therefore used exclusively in severely burned patients for
whom hospitalisation duration is longer and multiple surgi-
cal and grafting operations are needed. It is worth mention-
Figure 2: Different stages of development. In Switzerland, the use of human fetal cells and adult cells is part of a Federal Transplantation Pro-
gramme (blue), whereas the use of human cells at earliest stage requires a license (red).
Figure 3: Autologous and allogeneic cell therapy performed at the CHUV Burn Centre. Cell culture is required for each patient for autologous
transplants, whereas for an allogeneic transplant, a single organ donation creates a cell bank that can treat multiple patients and significantly
reduce the time-to-treatment. CEA = cultured epithelial autograft; CDEA = cultured dermal-epithelial autograft; BB = biological bandage
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ing that systematic prophylactic use of antibiotics prior to
a skin autografting is not recommended, to avoid promot-
ing resistance; however, in the case of a cell-based therapy
such as CEA or CDEA, it is common practice at CHUV to
prepare recipient sites 2 days prior to grafting by a daily
application of gentamicin and/or terbinafine, according to
the targeted pathogen.
During the 3–7 weeks required for preparation of CEA and
CDEA, patients are covered with temporary skin substi-
tutes to prevent fluid loss, reduce infection risk and de-
crease pain by nerve covering [28]. Over the years, tem-
porary skin substitutes have included xenogeneic
decellularised porcine skin, allogenic cadaveric human
skin and synthetic dressings [29], all of which carry some
risk of rejection and disease transfer. Furthermore, the fre-
quent integration of temporary covers by the recipient ren-
ders ablation difficult with painful eschars [27]. In early
2000, a new allogenic cell therapy was developed in the
Regenerative Therapy Unit at the CHUV: use of biological
bandages made of human progenitor skin fibroblasts seed-
ed onto biodegradable equine collagen scaffolds (fig. 4b).
The function of these bandages was to replace other tem-
porary dressings that had many clinical complications.
These bioactive bandages allow simultaneous enhance-
ment of skin regeneration, which is most likely related to
their release of growth factors and cytokines [30]. The first
clinical trials, begun in 2000, demonstrated that biological
bandages provided efficient treatment of second degree su-
perficial and deep burns without autografting, showing that
progenitor skin cells may have great potential to treat burns
and, eventually, acute and chronic wounds of other types
[20]. Biological bandages have since been used routinely
at the CHUV, particularly for paediatric burns.
Beginning in the early 2000s, use of platelet rich plasma
[31] was integrated into patient care. Local application of
platelet rich plasma has been shown to improve healing in
donor sites [32] (fig. 4c).
It is worth mentioning that a new Federal Act on Trans-
plantation of Organs, Tissues and Cells came into force
in 2007.This involved implementation of good manufac-
turing practice (GMP) procedures for cell therapy prepa-
ration [33]. Thus, a cell production centre was initiated as
part of the CHUV’s 2009–2013 strategic plan. Since 2015,
all types of cell therapy are manufactured at the Cell Pro-
duction Centre, which is an accredited GMP facility in
Switzerland for cell therapy production, not only for clin-
ical trials but also for routine preparation of cell therapies
for burn patients. A summary of the different cell therapies
for burns can be found in table 1.
Different indications for a cell therapy in burn
patients
When burns are deep (second and third degree burns), the
skin loses its ability to regenerate and a skin graft is re-
quired. Split-thickness autografting is still the gold stan-
dard for the treatment of deep burn wounds [27]. This
consists of taking from the patient epidermis with a small
portion of the dermis in order to cover the burn wound (the
donor site heals spontaneously by re-epithelialisation be-
cause of the remaining dermis portion). However, for se-
verely burned patients, when the damaged surface is too
Figure 4: Different types of cell therapy used at the CHUV Burn Centre. [a] Cultured epidermal autograft and cultured dermal-epidermal auto-
graft (CEA and CDEA) – keratinocytes are cultured on feeder cell layers for cell expansion, fibroblasts are retrieved from dermis explants (left
panel). In the case of a CDEA, parallel culture of fibroblasts is done, and the keratinocytes are applied on the fibroblast layer after expansion.
Finally, the cell sheet (middle panel) is washed with PBS and applied on patient with gauze (right panel). [b] Biological bandage (BB) – a vial
from the cell bank (left panel) is thawed, and cells are seeded on a collagen matrix and incubated overnight in culture medium (middle panel),
then washed and applied to patient (right panel). [c] Platelet rich plasma (PRP) – blood is collected, centrifuged in a two-step process to iso-
late platelets, which are then applied to the patient.
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large to be covered by autografting, cell therapy is need-
ed. The appropriate type of cell therapy depends on the to-
tal body surface area (TBSA) and the depth of the burn. A
CEA strategy is used for adult burn patients with a deep
burn surface that exceeds 40–50% of the TBSA. The sur-
geon may also decide to use a CDEA for the areas where
he/she considers it to be necessary, such as the hands or
other body areas that require a certain functionality. How-
ever, this is only done in patients where it is known that
hospitalisation will be for a long time, permiting cell cul-
turing (generally for very severe burns).
Biological bandages serve as a temporary cover, allowing
the time to prepare CEAs and/or CDEAs. They can also
be used to cover donor graft sites to stimulate wound clo-
sure and in combination with a mesh graft in a “sandwich-
like” configuration. Likewise, platelet rich plasma is used
in burns to stimulate and accelerate the healing of wounds
with large surfaces.
For paediatric burn patients at the CHUV, it is standard
to use biological bandages to cover burns of 10% TBSA
or more, since this is the definition of a severe burn in
paediatric patients. Every 2 days the biological bandages
are replaced by new ones, and this process is normally re-
peated up to four times. After 10 days, the surgeon as-
sesses the wound closure and decides if a skin autograft is
required for surface areas that are not completely closed.
Most paediatric burns at CHUV are second degree super-
ficial burns that are appropriately treated with biological
bandages, with complete wound closure usually within 10
days, thus decreasing the necessity of skin autografting. In
addition, CEA and CDEA can also be used in paediatric
burn patients (>40% TBSA), but these are fortunately rare
cases in the CHUV. A summary of the different cases for
cell therapies used can be found in table 2.
Ongoing projects in cell therapies and perspec-
tives
Skin wounds are major contributors to global disease bur-
den, affecting millions of people worldwide [34]. This bur-
den is expected to increase, with serious consequences in
the future as over half of all chronic and acute skin wounds
become infected [35]. Such infections are particularly wor-
risome in the context of the rise in resistance of bacteri-
al pathogens to antibiotic treatments [36, 37]. In this con-
text, research efforts are ongoing at the CHUV to develop
a new generation of biological bandages with antimicro-
bial properties to treat bacterial infections topically. For bi-
ological bandage production, the use of collagen scaffolds
for progenitor cell support may be more prone to infec-
tion because of their high hydroxyproline content, which is
a source of nutrients for opportunistic bacterial pathogens
such as Pseudomonas aeruginosa [38]. In 2016, Abdel-
Sayed and co-authors showed that coupling the collagen
matrix with a certain class of antimicrobial peptide den-
drimers not only inhibited the growth of multi-drug resis-
tant Pseudomonas aeruginosa, but also could have pro-an-
giogenic effects, which are involved in improved wound
healing [39]. A preclinical study testing the safety and ef-
ficacy of these new class of bandages is currently ongo-
ing. Meanwhile, the CHUV also has other successful cell
therapy endeavours. For instance, in 2018 the first patient
was treated with a matrix-assisted autologous chondrocyte
transplant. This was the first clinical protocol for cell ther-
apy to be accepted in Switzerland with full GMP process-
ing in association with the Cell Production Centre of the
CHUV. Cell therapy research is also undertaken in Zurich,
where the second national centre of “highly specialised
medicine” for burn care management is situated; an exam-
Table 1: Summary of different cell therapies used at the CHUV Burn Centre.
Type of therapy Description Type of biopsy Type of cells
(type of graft)
CEA Cultured epithelial autograft Epidermal Keratinocytes
(autologous)
CDEA Cultured dermal-epithelial autograft Epidermal and dermal Fibroblasts and keratinocytes
(autologous)
BB Biological bandage No biopsy: off-the-shelf cell bank Human progenitor fibroblasts
(allogenic)
PRP Platelet rich plasma Blood Platelets
(autologous)
Table 2: Different indications for the use of cell therapies at the CHUV Burn Centre, as well as the average number of patient per year that benefited from each therapy for the
past 5 years. The time delay before receiving a cell therapy varies depending on the type of treatment: the need for a cell culture step considerably prolongs the preparation time
before transfer to the patient. Note that biological bandages and platelet rich plasma can be transferred within 24–72 hours and less than 24 hours, respectively, after prepara-
tion.
Adult Child Use and indication Burned surface Duration of preparation Number of patients/year
Cultured epithelial autograft + + Applied directly on wounds
Applied in “sandwich” with
skin mesh grafts
On autograft donor sites
>40–50% 2–3 weeks* 11
Cultured dermal-epithelial
autograft
+ + Very rare cases, for long
hospital stays only
>70–80% 6-8 weeks 2
Biological bandage + + Temporary cover on areas
needing further grafting
On autograft donor sites
Starting from: >20%
for adults; >10% for
children
24–72 hours 9
Platelet rich plasma + – For any type of burn
On autograft donor sites
>1–2% <24 hours 115
* This preparation time can be reduced to 1 week if cultured epithelial autograft is delivered by spray. In general, the spray alternative is used when the condition of the patient
does not allow longer wait periods.
Review article: Biomedical intelligence Swiss Med Wkly. 2019;149:w20079
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 5 of 7
ple is experimentation of bio-printing in order to one day
be able to produce skin for patients in some sort of skin
factory, in a fast, accurate and efficient way.
The European Directives and Regulations (2001/83/EC
and 1394/2007) classified cell therapies as “Advanced
Therapy Medicinal Products” (ATMP) as of 2008, which
imposes industrial GMP requirements, as well as market-
ing authorisation, for cell therapy production in hospital
settings. This in turn has increased the costs considerably
and could lengthen the process of introducing new treat-
ments for burn patients [33]. Hence, it is important to dis-
cuss with health authorities about hospital exemptions to
allow compassionate use of cell therapies, without the re-
quirement for marketing authorisation, to make these cus-
tomised and life-saving treatments available to patients
[40–42]. From January 2019, revisions of the Therapeutic
Products Act (Stage 2), which aim to simplify and facilitate
patient access to medicinal products and improve condi-
tions for biomedical research, have come into force. In par-
ticular, this allows a 2-year authorisation for the “compas-
sionate use” of cell therapies provided that a clinical study
has been approved in Switzerland prior to the request. Sci-
entific research continues to advance therapeutic possibil-
ities in tissue engineering and regenerative medicine, even
as current possibilities for patient care are hampered by the
hurdles of GMP procedures, increased administrative load
and costs. It is of course in the best interest of physicians
and scientists that these hurdles are removed by the com-
petent authorities to ensure that patients have access to the
best treatment options and with the highest security at all
times.
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